During the past decade, Sunnybrook Research Institute conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 16 clinical trials were completed, i.e. on average, 27.6% percent of trials that started reached the finish line to date. In the past 5 years, 32 clinical trials started and 12 clinical trials were completed. i.e. 37.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sunnybrook Research Institute" #1 sponsor was "Pfizer" with 11 trials, followed by "Sunnybrook Health Sciences Centre" with 9 trials sponsored, "Merck Sharp & Dohme LLC" with 6 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored and "InSightec" with 3 trials sponsored. Other sponsors include 34 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sunnybrook Research Institute" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator and "Eisai Inc." with 2 trials as a collaborator. Other collaborators include 31 different institutions and companies that were collaborators in the rest 38 trials.

According to Clinical.Site data, the most researched conditions in "Sunnybrook Research Institute" are "Amyotrophic Lateral Sclerosis" (4 trials), "Prostate Cancer" (3 trials), "ALS" (2 trials), "Brain Tumor" (2 trials) and "Malignant Melanoma" (2 trials). Many other conditions were trialed in "Sunnybrook Research Institute" in a lesser frequency.

Most popular intervention types in "Sunnybrook Research Institute" are "Drug" (49 trials), "Other" (13 trials), "Device" (10 trials), "Biological" (7 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Pembrolizumab" (9 trials), "Enzalutamide" (4 trials), "Cisplatin" (3 trials) and "Palbociclib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Sunnybrook Research Institute" are 55 trials for "All" genders, 9 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are 47 active trials in "Sunnybrook Research Institute". 1 are not yet recruiting, 21 are recruiting, 24 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 10 completed trials in Sunnybrook Research Institute, 1 suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Sunnybrook Research Institute, 3 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 17 trials that are defined as “Not Applicable".